Abstract
Myocardial infarction (MI) remains a leading cause of global mortality, with the immune and coagulation systems playing pivotal roles in its pathophysiology. This study aimed to identify biomarkers associated with immune-related genes (IRGs) and coagulation-related genes (CRGs) in MI and to explore their potential regulatory mechanisms in treatment. Data from the GSE61144 and GSE60993 datasets were utilized. Four genes (IGF2R, TGFA, PLAUR, and MAPK14) were identified, exhibiting significantly elevated serum levels in patients with MI. Their distribution across tissues and single cells was further analyzed. Methylation site analysis of the N6-methyladenosine (m(6)A) biomarker revealed high-confidence methylation sites in IGF2R, PLAUR, and MAPK14. The RNA-binding protein (RBP) interactions were examined, revealing high-affinity binding sites for TARDBP in both IGF2R and MAPK14. GeneMANIA analysis highlighted biomarker-associated genes enriched in positive kinase regulation. Furthermore, a total of 20 potential drugs were predicted, with albuterol sulfate identified as a target for IGF2R, and molecular docking confirming the strongest binding affinity in the IGF2R-albuterol sulfate complex. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1038/s41598-025-24313-z.